Ideal candidates for nivolumab are typically those with advanced or metastatic gynecologic cancers that have not responded to conventional treatments. Biomarker testing, such as PD-L1 expression levels, can also help identify patients who are more likely to benefit from nivolumab therapy. However, the final decision should be made based on a comprehensive evaluation by an oncologist.
